Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.62 |
| ▸ | LAP3 | P28838 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288565 | 0.90 | FFAR1 (0.67) | LTA4HLAP3FFAR1FFAR4PARP10 | |
| SCHEMBL13452451 | 0.85 | EPHX1 (0.57) | LTA4HLAP3 | |
| SCHEMBL20717804 | 0.85 | EPHX1 (0.57) | LTA4HLAP3 | |
| Hydrochloric Acid SCHEMBL20704531 | 0.84 | EPHX1 (0.55) | LTA4H | |
| Hydrochloric Acid SCHEMBL20704533 | 0.84 | EPHX1 (0.55) | LTA4H | |
| SCHEMBL5888154 | 0.82 | LTA4H (0.67) | LTA4HLAP3FFAR1FFAR4PARP10 | |
| SCHEMBL289033 | 0.82 | LTA4H (0.67) | LTA4HLAP3FFAR1FFAR4PARP10 | |
| SCHEMBL5358938 | 0.81 | LTA4H (0.74) | LTA4HLAP3FFAR1FFAR4PARP10 | |
| SCHEMBL2032141 | 0.81 | LTA4H (0.74) | LTA4HLAP3FFAR1FFAR4PARP10 | |
| SCHEMBL2027392 | 0.81 | LTA4H (0.74) | LTA4HLAP3FFAR1FFAR4PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | LTA4H 31/4885LAP3 151/4885FFAR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.